CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy

Ke, Chien-Chih; Liu, Ru‐Shi; Yang, An Hang; Liu, Ching Sheng; Wen, Chin; Tseng, Ling Ming; Tsai, Yi Fan; Ho, Jennifer H.; Lee, Chen Hsen; Lee, Oscar K.

doi:10.1007/s00259-012-2242-5

Cited by 47 publications

(45 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, such spheres maintained an undifferentiated state (UPTC), as confirmed by morphological analysis (Fig. 1A) and the expression of stem cell markers such as CD133 (data not shown), as found in previous studies (17,22). Morphological analysis revealed that these cell cultures were exclusively formed by cellular clusters resembling so called 'tumor spheres'.…”

Section: Rna-binding Protein Musashi Is Expressed By Uptc Spheres Butsupporting

confidence: 90%

Resistance of papillary thyroid cancer stem cells to chemotherapy

Giuffrida¹,

Adamo²,

Iannolo³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Thyroid carcinoma is the most common endocrine neoplasm, with the highest mortality rate of all the endocrine cancers. Among the endocrine malignancies, ~80% are papillary thyroid carcinomas (PTCs). In the initiation and progression of this tumor, genetic alterations in the mitogen-associated protein kinase pathway, including RAS point mutations, RET/PTC oncogene rearrangements and BRAF point mutations, play an important role, particularly in deciding targeted therapy. In the present study, a small population of thyroid tumor cells, known as tumor spheres, were isolated and characterized from PTC surgical samples. These spheres can be expanded indefinitely in vitro and give rise to differentiated adherent cells when cultivated in differentiative conditions. The present study showed by reverse transcription-polymerase chain reaction and flow cytometric analysis that the undifferentiated PTC cells exhibited a characteristic antigen expression profile of adult progenitor/stem cells. The cells were more resistant to chemotherapeutics, including bortezomib, taxol, cisplatin, etoposide, doxorubicin and vincristine, than differentiated PTC cells and the majority possessed a quiescent status, as revealed by the various cell cycle characteristics and anti-apoptotic protein expression. Such advances in cancer thyroid stem cell biology may provide relevant information for future targeted therapies.

show abstract

Section: Rna-binding Protein Musashi Is Expressed By Uptc Spheres Butsupporting

confidence: 90%

Resistance of papillary thyroid cancer stem cells to chemotherapy

Giuffrida¹,

Adamo²,

Iannolo³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Hong et al previously reported that SUV max greater than 3.6 in distant metastases from DTC was significantly predictive of reduced disease-specific survival in multivariate analysis [19]. All of the patients with SUV max greater than 3.8 for LM in our study showed an increased TG level after and high resistance to 131 I therapy [20]. Therefore,…”

Section: Discussionmentioning

confidence: 56%

Association between Refractoriness to 131I Therapy for Differentiated Thyroid Carcinoma and 18F-FDG Accumulation in Lung Metastasis

Maruoka¹,

Baba²,

Isoda³

et al. 2017

Can Res

View full text Add to dashboard Cite

“…Conventional therapies target mature cancer cells and thus, thyroid CSCs, which are relatively quiescent and intrinsically resistant, are not eradicated (74,75). CSCs efficiently repair DNA damage following exposure to cytotoxic injury, and are therefore capable of reconstituting the original tumor (74).…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Cancer stem cells as a potential therapeutic target in thyroid carcinoma

Vicari¹,

Colarossi²,

Giuffrida³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract.A number of studies have indicated that tumor growth and proliferation is dependent on a small subset of cells, defined as cancer stem cells (CSCs). CSCs have the capability to self-renew, and are involved with cancer propagation, relapse and metastatic dissemination. CSCs have been isolated from numerous tissues, including normal and cancerous thyroid tissue. A regulatory network of signaling pathways and microRNAs (miRNAs) control the properties of CSCs. Differentiated thyroid carcinoma is the most common type of endocrine cancer, with an increasing incidence. Anaplastic thyroid carcinoma is the most rare type of endocrine cancer; however, it also exhibits the highest mortality rate among thyroid malignancies, with an extremely short survival time. Thyroid CSCs are invasive and highly resistant to conventional therapies, including radiotherapy and chemotherapy, which results in disease relapse even when the primary lesion has been eradicated. Therefore, targeting thyroid CSCs may represent an effective treatment strategy against aggressive neoplasms, including recurrent and radioresistant tumors. The present review summarizes the current literature regarding thyroid CSCs and discusses therapeutic strategies that target these cells, with a focus on the function of self-renewal pathways and miRNAs. Elucidation of the mechanisms that regulate CSC growth and survival may improve novel therapeutic approaches for treatment-resistant thyroid cancers.

show abstract

CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy

Cited by 47 publications

References 31 publications

Resistance of papillary thyroid cancer stem cells to chemotherapy

Resistance of papillary thyroid cancer stem cells to chemotherapy

Association between Refractoriness to 131I Therapy for Differentiated Thyroid Carcinoma and 18F-FDG Accumulation in Lung Metastasis

Cancer stem cells as a potential therapeutic target in thyroid carcinoma

Contact Info

Product

Resources

About